International Biotechnology Ord (LSE:IBT) - Investment trust price


Investment Trust Report

International Biotechnology Trust IBT

Last Price
GBX742.00

Day Change
-2.50|-0.34%

As of 24/06/2021
16:35:10 BST | GBX
Minimum 15 Minutes Delay.

Last Close744.50
Day Range737.00 - 748.00
52-Wk Range669.00 - 862.00
Mkt Cap Mil308.10
Yield %0.00
Estimated Nav759.67
Discount %-2.85
12M Avg Prem %0.42
Last Actual NAV759.67
Last NAV Date22/06/2021

Share Price Performance (GBP)

Key Statistics (GBP)
Total Assets312.156m
Net Assets312.156m
Market Capitalisation308.103m
Gross Gearing0%
Net Gearing7%
Average Daily Shares Traded (1 Yr)0.087m
Average Daily Value Traded (1 Yr)0.678m
Ongoing Charge (2020)1.29%
DomicileUnited Kingdom
Legal StructureClosed End Fund
Traded CurrencyGBP
ISINGB0004559349
Launch Date6 May 1994
Financial Year EndAug 2021
Next AGMDec 2021
NAV FrequencyDaily
Dividend FrequencySemi-annually
Valuation Statistics
 23/06/20211 Yr High1 Yr Low
Price738.00858.00688.00
NAV*759.67852.54681.60
Discount/Premium-2.854.24-6.95
Category Discount---
Z-Statistics (1Yr)-1.95  

Total Returns (GBP) 23/06/2021

 Chg (%)  
More ...
Price4.86 
NAV5.27
Cat Price1.81
Cat NAV2.51
 
Latest Dividends
TypeDividendEx-Dividend DateFinancial Year
Income14.200024/12/20202021
Income12.400016/07/20202020
Income12.400016/07/20202020
Income12.400019/12/20192020
Income14.000018/07/20192019
Director Dealings
TradedActionNotifierPriceAmountValue
21/12/2020PurchaseMr. Jim Horsburgh849.2615,000127,389.00
15/09/2020PurchaseMr. Patrick Magee792.003,50027,720.00
11/09/2020DDr. Veronique Bouchet733.8493682.00

Morningstar Rating™

5 Stars

Morningstar® Category

Sector Equity Biotechnology

Benchmarks

Morningstar® Benchmark

NASDAQ Biotechnology TR USD
Fund Structure
Share Type# of Shares
Ordinary Share41.384m

Investment Objective

The objective is to achieve long term capital growth by investing in high growth, development stage biotechnology companies that are either quoted or unquoted. The company invests in companies that are considered to be good value with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.
Managers
Kate Bingham01/05/2001
Ailsa Craig01/11/2006
Marek Poszepczynski02/09/2013

Directors

Veronique Bouchet, Kate Cornish-Bowden, Caroline Gulliver, Jim Horsburgh, Patrick Magee
Fund prices are updated every weekday after the close of trading and before 11 p.m. wherever possible. All figures are as at Last Close, on a cum income basis with debt valued at fair and in traded currency unless otherwise stated (we do not fair value debt for split capital trusts). Performance returns are presented in British Pounds (GBP) and calculated on a capital only basis with debt valued at par.
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.